Elagolix, a Novel, Orally Bioavailable GnRH Antagonist under Investigation for the Treatment of Endometriosis-Related Pain

@article{Ezzati2015ElagolixAN,
  title={Elagolix, a Novel, Orally Bioavailable GnRH Antagonist under Investigation for the Treatment of Endometriosis-Related Pain},
  author={M. Ezzati and B. Carr},
  journal={Women's Health},
  year={2015},
  volume={11},
  pages={19 - 28}
}
Suppression of estrogen production and reduction of menstrual blood flow are the mainstays of medical treatment of endometriosis-related pain and have been traditionally achieved by methods such as combined hormonal contraception, progestins and GnRH analogs, all with comparable efficacies, though different side-effect profiles. Elagolix is the frontrunner among an emerging class of GnRH antagonists, which unlike their peptide predecessors has a nonpeptide structure resulting in its oral… Expand

Paper Mentions

Blog Post
Overview of elagolix for the treatment of endometriosis
Elagolix as a Novel Treatment for Endometriosis-Related Pain.
New insights on the pathogenesis of endometriosis and novel non-surgical therapies
The potential role of elagolix for treating uterine bleeding associated to uterine myomas
...
1
2
3
...

References

SHOWING 1-10 OF 76 REFERENCES
Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
Aromatase inhibitors for the treatment of endometriosis.
Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.
Add-back therapy in the treatment of endometriosis: the European experience.
  • D. Edmonds
  • Medicine
  • British journal of obstetrics and gynaecology
  • 1996
Hormone treatment of endometriosis: the estrogen threshold hypothesis.
  • R. Barbieri
  • Medicine
  • American journal of obstetrics and gynecology
  • 1992
...
1
2
3
4
5
...